Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Scientists Speed Up Menopause, Causing Infertility In Crop-Destroying Pests
When scientist Loretta Mayer set out to alleviate diseases associated with menopause, she didn"t realize her work could lead to addressing world hunger and feeding hundreds of millions of people.
generic viagra online
Collaboration Between NC State And UNC Lineberger To Combat Non-Hodgkin Lymphoma In Human And Canine Patients
What do a college of veterinary medicine and a cancer treatment and research center have in common? The answer may be as plain as the nose on your dog"s face. Researchers from North Carolina State University"s College of Veterinary Medicine and the University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center are combining their expertise to pinpoint the cause of -- and improve treatments for -- non-Hodgkin lymphoma in human and canine patients.
News of the day
Des Moines Register Examines Planned Parenthood Of Greater Iowa 75 Years After Founding
The Des Moines Register on Friday profiled Planned Parenthood of Greater Iowa, which marks its 75th anniversary this year. Established in 1934 as the Iowa Maternal Health League, PPGI now includes 17 clinics offering a range of reproductive health services, as well as an education and re center. The organization originally was founded by four women with a mission of providing birth control for low-income married women. Over the years, it frequently "has been on the forefront of advances in reproductive history," according to the Register. For example, in the early 1960s, PPGI became the first provider in the Midwest to offer the oral contraceptive Ortho-Novum, leading to a more than 350% increase in its number of patients.Although antiabortion-rights advocates often discuss Planned Parenthood in relation to abortion services, the vast majority of its services are not abortion-related. Jill June, president and CEO of PPGI, said that although the organization"s services have greatly expanded since its founding, the "needs people have for the services we provide and the challenges we face in meeting those needs haven"t changed." She added, "People still face unintended pregnancies despite great technological advances in birth control and efforts to make contraception more available and to normalize contraception use" (Challender, Des Moines Register, 5/22).
Endocrinology

Can-Fite BioPharma To Initiate Phase I/II Clinical Trial With CF102 For The Treatment Of Hepatitis C Virus

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange announced that, following the approval by the Israel Ministry of Health and Rabin MC Ethics Committee, a phase I/II clinical trial with CF102 for the treatment of HCV will now start enrolling patients. The trial will investigate the safety and efficacy of CF102 in patients with HCV. This ascending-dose trial will be conducted at the Rabin Medical Center and include 32 patients. HCV is predominantly transmitted through body fluids and less frequently by sexual intercourse, and no vaccines are currently available. About 50% to 85% of HCV infected patients develop a chronic form of the disease, of whom 25% to 76% develop active chronic disease and cirrhosis, which is the leading cause of liver transplantation in Europe and the US and greatly increases the risk of liver cancer. Patients are currently offered drug therapy that generally consists of oral Ribavirin in combination with interferon injections. These drugs have severe adverse events and most patients rapidly become refractory to them. The market size today is more than 3 Billion $ and is estimated to grow to around 8.3 Billion $ on 2012. The Company previously reported that preclinical studies have suggested that the drug is active against HCV via inhibition of NS5, RNA dependent RNA polymerase. CF102 was also found to trigger programmed cell death (apoptosis) of liver cancer cells. The Company recently announced the successful completion of a Phase I clinical study with CF102 under an IND in the US, showing a safety profile and a linear pharmacokinetic behavior of the drug. Prof. Pnina Fishman, CEO of Can-Fite, said that "the initiation of the Phase I/II trial in HCV demonstrates the progress of the company in its clinical development program. Based on the definitive molecular mechanism of CF102 which targets the highly specific enzyme NS5 in the viral replication cycle, we have a great belief in the performance of the drug." In keeping with its financial reports, Can-Fite expects to release within weeks the results of a phase II clinical trial with CF101 for the treatment of Psoriasis. The company concluded successfully a Phase II study in Dry Eye Syndrome. Can-Fite BioPharma


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009